BFM
JNCE

Boothbay Fund Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Boothbay Fund Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,260
Closed -$75K – 921
2018
Q4 		$75K Buy
+22,260
New +$104K 0.01% 574

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Boothbay Fund Management's JNCE Position: Q1 2019 in Review

Boothbay Fund Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2019, closing a stake of 22,260 shares — an estimated $75K sold.

Boothbay Fund Management first reported a position in JNCE in Q4 2018 and held it in 1 quarter. The position peaked at $75K in Q4 2018. 80 funds tracked by Wall St. Rank hold JNCE as of Q1 2019.

  • Boothbay Fund Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Boothbay Fund Management sold 22,260 Jounce Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $75K.
  • Boothbay Fund Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Boothbay Fund Management's Jounce Therapeutics, Inc. Common Stock position peaked at $75K in Q4 2018.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Boothbay Fund Management's 13F filing for Q1 2019, filed 15 May 2019.